Showing 312 results
May 2023
-
Media ReleaseSandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMASubmissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trial Denosumab is indicated…
-
Media ReleaseNew Sandoz Board of Directors appointedNovartis Board of Directors approves the recommendation of Sandoz Chairman-designate for the future Sandoz Board of Directors, to start preparatory work in June, followed by formal constitution in H2…
-
Media ReleaseSandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilarsSandoz and Just - Evotec Biologics announce partnership to develop and manufacture multiple biosimilars with an option for expansion Sandoz gains access to proprietary AI-driven technology platform…
-
Media ReleaseSandoz developing Holzkirchen site into leading Biopharma Technical Development hub to support future biosimilar growthInvestment of EUR 25 million in building and equipment at Holzkirchen site, transforming lab building into a state-of-the-art biotech lab by Q4 2023 Site to become leading analytical…
-
Media ReleaseSandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicinesAgreement offers exclusive rights to commercialize six products in key areas of anti-infectives and oncology. Products from Adalvo slated for near- to mid-term launches, with four out of six…
April 2023
-
Media ReleaseNovartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidanceAd hoc announcement pursuant to Art. 53 LR Q1 sales grew +8% (cc1, +3% USD) and core operating income grew +15% (cc, +8% USD) Innovative Medicines (IM) sales grew +7% (cc, +3% USD) and core…
-
Media ReleaseSandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulationBiosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) is now approved in the EU for use in all indications of reference medicine Humira®* HCF formulation adalimumab…
March 2023
-
Media ReleaseSandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulationBiosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine Humira®* With this approval, Sandoz adalimumab HCF biosimilar will…
-
Media ReleaseSandoz signs Memorandum of Understanding to build new biologics production plant in Slovenia, to support increasing global demand for biosimilar medicinesSandoz investment expected to be at least USD 400m – MOU signed today in Ljubljana at ceremony led by Slovenian Prime Minister and Sandoz CEO New project underpins Sandoz ambition to drive future…
February 2023
-
Media ReleaseNovartis announces the appointment of the Chairman-Designate of Sandoz Board of DirectorsGilbert Ghostine, CEO of the Swiss multi-national fragrances business Firmenich appointed Chairman-Designate of the future Sandoz Board Mr Ghostine to begin role as Sandoz Chairman following the…
-
Media ReleaseSandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDASubmission supported by comprehensive analytical and clinical data package Denosumab indicated for treating variety of conditions including osteoporosis in postmenopausal women1,2 Sandoz continues to…